Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AcouSort ABOSTO:ACOU -3.87%50 Cash Ratio is 1.14 as of Mar. 2026, which is 53% below its 10-year median of 2.42. GuruFocus rates OSTO:ACOU with a GF Score™ of 50/100 and a GF Value™ of kr9.17 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,384 Biotechnology companies, AcouSort AB ranks worse than 70.95% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
AcouSort AB Cash Ratio Related Terms
AcouSort AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for AcouSort AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ACOU vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, AcouSort AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AcouSort AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AcouSort AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where AcouSort AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AcouSort AB (OSTO:ACOU) has a Cash Ratio of 1.14 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on AcouSort AB and its competitors. This is 53% below median its historical median of 2.42. Over the past decade, AcouSort AB's Cash Ratio has ranged from 0.22 to 12.33. According to the industry distribution chart, AcouSort AB ranks #982 out of 1384 companies in the Biotechnology industry, placing it in the top 71%.
Is AcouSort AB's Cash Ratio too high?
AcouSort AB's current Cash Ratio of 1.14 is 53% below median its 10-year median of 2.42. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 12.33. The Biotechnology industry median Cash Ratio is 2.93. AcouSort AB's value of 1.14 is 61.1% below this industry median. Based on the distribution chart, AcouSort AB ranks #982 out of 1384 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AcouSort AB has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AcouSort AB's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AcouSort AB ranks #982 out of 1384 companies for Cash Ratio. This places AcouSort AB in the lower half of its industry. The industry median Cash Ratio is 2.93. AcouSort AB's value of 1.14 is 61.1% below this benchmark. Historically, AcouSort AB's own Cash Ratio has ranged from 0.22 to 12.33 over the past decade. While the company's 10-year median is 2.42 vs. the industry median of 2.93, AcouSort AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AcouSort AB's current Cash Ratio of 1.14 is 61.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on AcouSort AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AcouSort AB's current Cash Ratio is 1.14, which is 53% below median its own 10-year median of 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AcouSort AB stock overvalued right now?
Based on GuruFocus' analysis, AcouSort AB (OSTO:ACOU) is currently considered Possible Value Trap. The stock's GF Value™ is kr9.17, compared to a current price of kr3.48 — trading 62.1% below its estimated fair value. The current Cash Ratio is 1.14, which is 53% below median its 10-year median of 2.42 and 61.1% below the Biotechnology industry median of 2.93. AcouSort AB's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For AcouSort AB (OSTO:ACOU), the current Cash Ratio is 1.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AcouSort AB (OSTO:ACOU) Overvalued in 2026?
Based on GuruFocus' analysis, AcouSort AB stock appears to be undervalued.
The current stock price of kr3.48 is trading 62.1% below its estimated GF Value™ of kr9.17.
GuruFocus considers AcouSort AB to be Possible Value Trap.
Key valuation signals for OSTO:ACOU:
Cash Ratio: 1.14 (53% below median its 10-year median of 2.42)
GF Value™: kr9.17 vs. price of kr3.48 (62.1% below fair value)
Industry Position: 61.1% below the Biotechnology median (#982 of 1384)
No single metric tells the full story. See the OSTO:ACOU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AcouSort AB is a company that specializes in products and solutions for the automated preparation of biological samples for researchers and life science companies. Its technology is based on using ultrasound to isolate, separate, or trap microscopic particles such as blood cells, bacteria, or extracellular vesicles in microfluidic channels. The company's products includes AcouTrap, AcouWash, and AcouPlasma.
50GF Score
Get the complete analysis for OSTO:ACOU
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ACOU has been successfully added to your 
